International Isotopes stock analysis
Want to see INIS full AI Analyst Report?
International Isotopes (INIS) Stock Price & Analysis
INIS Stock Chart & Stats
- Day’s Range
- $0.04 - $0.04
- 52-Week Range
- $0.03 - $0.10
- Previous Close
- $0.04
- Volume
- N/A
- Average Volume (3M)
- 81.28K
- Market Cap
- $19.03M
- Enterprise Value
- $45.05M
- Total Cash (Recent Filing)
- $1.20M
- Total Debt (Recent Filing)
- $9.21M
- Price to Earnings (P/E)
- 0.0
- Beta
- 1.28
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Diversified Isotope Applications
Exposure across medical, industrial, and research applications gives INIS multiple end markets for its isotope products and services. That breadth can support resilience and create opportunities to deepen customer relationships as isotope-based diagnostics and specialized uses develop over the medium term.
Strategic Refocus And Potential Funding
Exiting the uranium-asset project should narrow management attention toward the company’s established radioisotope segments. If regulatory closing conditions are met, the stated cash and stock consideration could strengthen flexibility for R&D, organic growth, and selective acquisitions.
Demonstrated Cash-generation Capacity
Although recent TTM cash flow was negative, positive operating cash flow in 2023–2025 and positive free cash flow in 2023 and 2025 show demonstrated cash-generation capacity. This provides a base for recovery if operating performance becomes more consistent.
Bears Say
Deteriorating Profitability
TTM revenue declined about 8%, while operating and EBITDA margins turned deeply negative and the net loss became extraordinarily large relative to revenue. This deterioration weakens internal funding capacity and makes near-term earnings quality and business stability less dependable.
Elevated Leverage
TTM debt-to-equity of about 2.7x, alongside an extreme 2025 debt reading, indicates a highly pressured capital structure. Elevated leverage can reduce financial flexibility, increase sensitivity to operating setbacks, and constrain investment in the isotope businesses.
Inconsistent Cash Flow
TTM operating and free cash flow were both negative, and annual cash results have swung between positive and negative. This inconsistency limits confidence that operations can reliably fund R&D, growth initiatives, or obligations without additional financing.
International Isotopes News
INIS FAQ
What was International Isotopes’s price range in the past 12 months?
What is International Isotopes’s market cap?
When is International Isotopes’s upcoming earnings report date?
How were International Isotopes’s earnings last quarter?
Is International Isotopes overvalued?
Does International Isotopes pay dividends?
What is International Isotopes’s EPS estimate?
How many shares outstanding does International Isotopes have?
What happened to International Isotopes’s price movement after its last earnings report?
Which hedge fund is a major shareholder of International Isotopes?
What is the TipRanks Smart Score and how is it calculated?
Company Description
International Isotopes
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Shahe Bagerdjian
- Employees
- 45
- Website
- radnostix.com
- Address
- 4137 Commerce Circle, Idaho Falls, ID, 83401, US
International Isotopes (INIS) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 14 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |











